Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis.

Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA19 Jan 2006Cited by 33 (Europe PMC)

PMID16421647DOI10.1007/s00198-005-2002-5PepBankPUB-16421647

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Taiwanese postmenopausal women with osteoporosis, teriparatide increased spinal BMD more than calcitonin.
In plain wordsIn women with osteoporosis, teriparatide increased spinal bone density more than calcitonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 63
Comparator
Salmon calcitonin 100 IU daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Spinal BMD increase
4.5%
teriparatide
Spinal BMD increase
0.1%
calcitonin
Source sentences
Summary
The results at 6 months showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%), but the BMD changes in these two groups at the femoral neck and the total hip were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164701
02HumanRandomized controlled trialEfficacy outcome
In these women, teriparatide increased bone specific alkaline phosphatase more than calcitonin.
In plain wordsIn these women, teriparatide increased a bone formation marker more than calcitonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone specific alkaline phosphatase
Study
n = 63
Comparator
Salmon calcitonin 100 IU daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Bone specific alkaline phosphatase increase
142%
teriparatide
Bone specific alkaline phosphatase increase
37%
calcitonin
Source sentences
Summary
There were also larger mean increases in bone markers in the teriparatide group than in the calcitonin group (bone specific alkaline phosphatase 142% vs. 37%; osteocalcin 154% vs. 23%).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164704
03HumanRandomized controlled trialEfficacy outcome
In these women, teriparatide increased osteocalcin more than calcitonin.
In plain wordsIn these women, teriparatide increased osteocalcin more than calcitonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteocalcin
Study
n = 63
Comparator
Salmon calcitonin 100 IU daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Osteocalcin increase
154%
teriparatide
Osteocalcin increase
23%
calcitonin
Source sentences
Summary
There were also larger mean increases in bone markers in the teriparatide group than in the calcitonin group (bone specific alkaline phosphatase 142% vs. 37%; osteocalcin 154% vs. 23%).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164705
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, salmon calcitonin produced a smaller spinal BMD increase than teriparatide at 6 months (0.1% versus 4.5%).
In plain wordsIn women with osteoporosis, salmon calcitonin produced a smaller spinal bone density increase than teriparatide.
Peptide
Calcitonin-salmon
Outcome
DecreaseLumbar spine BMD change
Study
n = 63
Comparator
Teriparatide 20 microg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Spinal BMD change
0.1%
calcitonin
Spinal BMD change
4.5%
teriparatide
Source sentences
Summary
The results at 6 months showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%), but the BMD changes in these two groups at the femoral neck and the total hip were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164706
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, femoral neck BMD changes between the salmon calcitonin and teriparatide groups were not significant at 6 months.
In plain wordsIn women with osteoporosis, femoral neck bone density changes were not significant between the salmon calcitonin and teriparatide groups.
Peptide
Calcitonin-salmon
Outcome
No significant changeFemoral neck BMD change
Study
n = 63
Comparator
Teriparatide 20 microg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
The results at 6 months showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%), but the BMD changes in these two groups at the femoral neck and the total hip were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164707
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, total hip BMD changes between the salmon calcitonin and teriparatide groups were not significant at 6 months.
In plain wordsIn women with osteoporosis, total hip bone density changes were not significant between the salmon calcitonin and teriparatide groups.
Peptide
Calcitonin-salmon
Outcome
No significant changeTotal hip BMD change
Study
n = 63
Comparator
Teriparatide 20 microg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
The results at 6 months showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%), but the BMD changes in these two groups at the femoral neck and the total hip were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164708
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, salmon calcitonin produced a smaller bone-specific alkaline phosphatase increase than teriparatide (37% versus 142%).
In plain wordsIn women with osteoporosis, salmon calcitonin increased bone-specific alkaline phosphatase less than teriparatide.
Peptide
Calcitonin-salmon
Outcome
DecreaseBone-specific alkaline phosphatase change
Study
n = 63
Comparator
Teriparatide 20 microg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Bone-specific alkaline phosphatase change
37%
calcitonin
Bone-specific alkaline phosphatase change
142%
teriparatide
Source sentences
Summary
There were also larger mean increases in bone markers in the teriparatide group than in the calcitonin group (bone specific alkaline phosphatase 142% vs. 37%; osteocalcin 154% vs. 23%).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164709
08HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, salmon calcitonin produced a smaller osteocalcin increase than teriparatide (23% versus 154%).
In plain wordsIn women with osteoporosis, salmon calcitonin increased osteocalcin less than teriparatide.
Peptide
Calcitonin-salmon
Outcome
DecreaseOsteocalcin change
Study
n = 63
Comparator
Teriparatide 20 microg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Osteocalcin change
23%
calcitonin
Osteocalcin change
154%
teriparatide
Source sentences
Summary
There were also larger mean increases in bone markers in the teriparatide group than in the calcitonin group (bone specific alkaline phosphatase 142% vs. 37%; osteocalcin 154% vs. 23%).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
Report a problemFND-1642164710

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with established osteoporosis, femoral neck BMD changes at 6 months were not significant in the teriparatide and calcitonin groups.
In plain wordsIn women with osteoporosis, femoral neck bone density changes at 6 months were not significant in the teriparatide and calcitonin groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD
Study
n = 63
Comparator
Salmon calcitonin 100 IU daily
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The results at 6 months showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%), but the BMD changes in these two groups at the femoral neck and the total hip were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1642164702
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with established osteoporosis, total hip BMD changes at 6 months were not significant in the teriparatide and calcitonin groups.
In plain wordsIn women with osteoporosis, total hip bone density changes at 6 months were not significant in the teriparatide and calcitonin groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD
Study
n = 63
Comparator
Salmon calcitonin 100 IU daily
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The results at 6 months showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%), but the BMD changes in these two groups at the femoral neck and the total hip were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan.
Summary · context
This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis.
Summary · context
They were randomized to receive either teriparatide 20 microg or calcitonin 100 IU daily in an open-label fashion.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1642164703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis.

Summary

Results from this study10

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms